Filing Flows › Health Care › Rockwell Medical (RMTI)
Rockwell Medical (RMTI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Rockwell Medical (RMTI) Q2 2026 earnings results →
Q2 2026 Revenue up 11% year over year to $17.8M · 7¢ of every $1 of revenue lost · operating margin -6.0%
Rockwell Medical made $17.8M in Q2 2026 (+11% Y/Y). Operating margin -6.0%, net loss $1.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $17.8M in Q2 2026, up 11% year over year and up 3% from the previous quarter.
Gross margin was 18.2%, up 2.7 points from Q2 2025. Operating costs exceeded revenue by $1.1M, an operating margin of -6.0%. Operating expenses grew 12% against revenue growth of 11%. The fastest-growing cost line was General & admin (+12%). The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $1.6M loss.
Operating cash flow was $2.1M (up 13% year over year). Non-cash charges added back $492K of depreciation and amortization and $403K of share-based compensation. Working capital and other items added $2.4M. Capital expenditures of $617K left free cash flow of $1.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $17.8M | +11% | -6.0% | −$1.2M | $2.1M |
| Q1 2026 | 10-Q | May 7, 2026 | $17.3M | -8% | -8.5% | −$1.6M | −$167K |
| Q4 2025 | 10-K | Mar 26, 2026 | $18.3M | -26% | -2.2% | −$554K | $2.3M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $15.9M | -44% | -9.9% | −$1.8M | −$1.3M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $16.1M | -38% | -8.4% | −$1.5M | $1.8M |
| Q1 2025 | 10-Q | May 12, 2025 | $18.9M | -17% | -7.2% | −$1.5M | −$3.5M |
| Q4 2024 | 10-K | Mar 20, 2025 | $24.7M | +12% | -2.1% | −$756K | $865K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Rockwell Medical
Unless otherwise indicated in this Annual Report on Form 10-K “we,” “our,” “us,” “the Company,” "Rockwell," “Rockwell Medical,” and other similar terms refer to Rockwell Medical, Inc., together with its consolidated subsidiaries. You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission (“SEC”). In particular, please read our definitive proxy statement, which will be filed with the SEC in connection with our 2026 annual meeting of stockholders, our quarterly reports on Form 10-Q and any current reports on Form 8-K that we may file from time to time. You can access free of charge on our website copies of these reports as soon as practicable after they are electronically filed with the SEC.
In its own words, from its 10-K, filed Mar 26, 2026.
Rockwell Medical against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +10%. Operating margin: -6.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RMTI Rockwell Medical | Q2 2026 | $17.8M | +11% | -6.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Rockwell Medical 10-Q on SEC EDGAR · CIK 1041024 · Pharmaceutical Preparations
More on RMTI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results